Eli Lilly's rheumatoid arthritis drug Olumiant, in combination with Gilead's Remdesivir, was found to reduce recovery time...

 ...for hospitalized COVID-19 patients. The drugmaker is now seeking an emergency use authorization from the FDA for the anti-inflammatory. Olumiant currently holds preferred status under the pharmacy benefit for just 11% of covered lives, with utilization management restrictions. The drug is not covered for 25% of all insured lives.

SOURCE: MMIT Analytics, as of 9/16/20